Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 6Phase 1 6Phase NA 5Phase EARLY_PHASE1 4Phase 1/2 4

Status

Recruiting 14Completed 13Unknown 5Terminated 4Active not recruiting 4Withdrawn 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

NET 4Endocrine 4Thoracic 2Genitourinary 2Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 46Colorectal Neoplasms 42Neoplasms 41Neoplasm Metastasis 34Melanoma 31Multiple Myeloma 30Prostatic Neoplasms 29Recurrence 28Stomach Neoplasms 27Pancreatic Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lung Neoplasms 25Carcinoma, Renal Cell 25Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Leukemia, Myeloid, Acute 22Triple Negative Breast Neoplasms 21Lymphoma, Non-Hodgkin 21Lymphoma, Follicular 21Leukemia, Lymphocytic, Chronic, B-Cell 19Glioblastoma 18Uterine Cervical Neoplasms 16Myelodysplastic Syndromes 16Lymphoma 16Colonic Neoplasms 15Carcinoma, Transitional Cell 15Lymphoma, Mantle-Cell 14Leukemia 14

Interventions

lutetium Lu 177 dotatate 1avelumab 1atezolizumab 1Radiotherapy 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Neuroendocrine Tumors × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT02749331 2024-12-03

RADNET

Uppsala University

Phase 1/2 Active not recruiting
35 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05199272 2024-11-15

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

23andMe, Inc.

Phase 1/2 Active not recruiting
141 enrolled
EndocrineGenitourinaryGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡